| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05808881 Details | 2023-07-12 Interventional | 4 | 0 | Nalmefene Naloxone Opiate Overdose Opioid Overdose | Due to changes in research objectives and methodological approach. - | |||
| NCT04090697 Details | 2023-07-12 Interventional | 1/2 | - | Oxandrolone Heart Defects, … Heart Diseases Hypoplastic Lef… Congenital Hear… Hypoplastic Lef… | FDA withdrawal of Oxandrin NDA and generic ANDAs - | |||
| NCT03970616 Details | 2023-07-12 Interventional | 1/2 | 27 | Durvalumab Tivozanib Carcinoma Carcinoma, Hepa… Hepatocellular … | The study was terminated due to regulatory approval of newer therapeutic options and slower
than anticipated accrual. - | |||
| NCT02011971 Details | 2023-07-12 Interventional | 1/2 | - | Vinpocetine Epilepsy | We are now considering revision of the IND to determine maximum tolerated dose - | |||
| NCT05760261 Details | 2023-07-11 Interventional | 1 | - | Midazolam Urinary Tract I… | To allow analysis of data from supplementary non-clinical study. - | |||
| NCT05255666 Details | 2023-07-11 Interventional | 2 | 0 | Irinotecan Pembrolizumab Brain Neoplasms Breast Neoplasm… Neoplasm Metast… Triple Negative… Brain Metastase… Triple Negative… | No drug - | |||
| NCT04781374 Details | 2023-07-11 Interventional | 2 | 0 | Neratinib Adenocarcinoma Prostatic Neopl… Castration-resi… Metastatic Pros… Prostate Cancer Prostate Cancer… | Withdrawal of funding - | |||
| NCT03722498 Details | 2023-07-11 Interventional | 2 | 0 | Fluorouracil Leucovorin Oxaliplatin Sorafenib Carcinoma Carcinoma, Hepa… Hepatocellular … | No patients join - | |||
| NCT03690869 Details | 2023-07-10 Interventional | 1/2 | 57 | Cemiplimab Central Nervous… Diffuse Intrins… Glioma Neoplasms Nervous System … High Grade Glio… Refractory Cent… Refractory Soli… Relapsed Centra… Relapsed Solid … | Sponsor Decision - | |||
| NCT03637764 2018-000390-67 Details | 2023-07-10 Interventional | 1/2 | 107 | Atezolizumab Neoplasms Neoplasm | Study was stopped after interim analysis for 4 cohorts (HCC, SCCHN, EOC, and GBM) indicated
that the results did not fulfill the preplanned interim analysis criteria to move to Phase 2
stage 2 in all 4 cohorts. Study was stopped after performance of interim analysis for 4 cohorts (Cohort A [HCC], Cohort B [SCCHN], Cohort C [EOC] & Cohort D-1 [GBM]) as the efficacy results observed in each cohort did not fulfill the pre-planned interim analysis criteria allowing the study to move to Phase 2 Stage 2 in these 4 cohorts. | |||
| NCT02530437 Details | 2023-07-10 Interventional | 1/2 | 7 | Albumin-Bound P… Carboplatin Paclitaxel Adenocarcinoma Esophageal Neop… Gastroesophagea… Stage IB Esopha… Stage II Esopha… Stage IIA Esoph… Stage IIB Esoph… Stage IIIA Esop… Stage IIIB Esop… | The sponsor sold the drug TALADEGIB to another company during the trial and thereafter no drug
was available. The sponsor made a decision to stop development of this drug Taladegib. - | |||
| NCT05643170 Details | 2023-07-07 Interventional | 3 | 4 | Trospium chlori… Xanomeline Schizophrenia | Company's business decision. - | |||
| NCT04112199 Details | 2023-07-07 Interventional | 2 | 15 | Terlipressin Ascites Fibrosis Liver Cirrhosis Decompensated C… | For reasons unrelated to safety or efficacy - | |||
| NCT02584634 2015-001879-43 Details | 2023-07-07 Interventional | 1/2 | 43 | Avelumab Crizotinib Carcinoma, Non-… Lung Neoplasms Non-Small Cell … | The study was terminated since there was no need for further safety or efficacy data to be
collected. The participants having benefit from the Investigational treatments have been moved
to a continuation study (NCT05059522) Enrollment in the study was terminated early based on the changing landscape in treatment options for treatment naïve ALK positive NSCLC. This decision was not due to any safety concerns or regulatory interactions. All participants on active treatment at the time of the early enrollment termination could continue treatment and follow up per the protocol. | |||
| NCT05934097 Details | 2023-07-06 Interventional | 1 | 0 | Bendamustine Hy… Cyclophosphamid… Doxorubicin Prednisone Rituximab Vincristine Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Lymphoma, Mantl… Diffuse Large B… Follicular Lymp… Mantle Cell Lym… Marginal Zone L… Transformed Ind… | This study was withdrawn (Sponsor decision). - | |||
| NCT03890289 Details | 2023-07-06 Interventional | 2 | 5 | Idelalisib Obinutuzumab Lymphoma Lymphoma, Folli… Follicular Lymp… | Study was halted prematurely due to safety, since tocity stopping rules have been met - | |||
| NCT00750698 Details | 2023-07-06 Interventional | 2 | 8 | Entinostat Erlotinib Hydro… Carcinoma, Non-… Lung Neoplasms Non Small Cell … | Due to business reasons, enrollment on the study was halted and the study terminated. The
decision to close enrollment was not due to any safety concern. Due to business reasons, enrollment on the study was halted and the study terminated. | |||
| NCT05079789 2019-002607-18 Details | 2023-07-05 Interventional | 3 | 20 | Amiloride Furosemide Hypernatremia Nephrosis Nephrotic Syndr… Syndrome Edema Sodium Retentio… | Low recruiting rate and decision to evaluate as pilot study - | |||
| NCT04897217 Details | 2023-07-05 Interventional | 3 | 0 | Levonorgestrel Megestrol Megestrol Aceta… Endometrial Hyp… Hyperplasia | PI decision - | |||
| NCT04404361 Details | 2023-07-05 Interventional | 2 | 200 | Janus Kinase In… COVID-19 COVID COVID19 | decision to close enrollment early - |